Biological therapies are transforming cancer treatment by harnessing the body’s own immune system and cellular mechanisms.

Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...

Durable, ongoing near-complete response to nivolimab + relatlimab in a 64 year old with locally-advanced BCC after resistance to 26 wks of nivolimab alone. A new study led by researchers at the Johns ...

– Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive ...

Basal cell carcinoma (BCC) represents the most prevalent form of skin cancer, with research efforts increasingly focused on elucidating its molecular underpinnings and improving therapeutic strategies ...

Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...